The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Open accessAbstract
BACKGROUNDCoronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; however, in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options.METHODSWe performed a flow cytometric characterization of immune cell subsets from 30 patients with COVID-19 and correlated these data with clinical outcomes.RESULTSPatients with COVID-19 showed decreased numbers of circulating T, B, and NK cells and exhibited a skewing of CD8+ T cells toward a terminally differentiated/senescent phenotype. In agreement, CD4+ T and CD8+ T, but also NK cells, displayed reduced antiviral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in patients with COVID-19, particularly in those who required intensive care. The latter group of patients also showed increased serum IL-6 levels that inversely correlated to the frequency of granzyme A-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells.CONCLUSIONThe association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore antiviral mechanisms.FUNDINGThis study was supported by funds from the Department of Experimental and Clinical Medicine of University of Florence (the ex-60% fund and the "Excellence Departments 2018-2022 Project") derived from Ministero dell'Istruzione, dell'Università e della Ricerca (Italy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For CD8+ T cells, there are reports of diminished CD8+ cytotoxicity and cytokine production in severe cases126,132, while others report the opposite141, and still others find no differences142.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [142]
In the citing paper
“Some studies have found reduced effector functions for CD4+ T cells, i.e. IFNγ/IL-2/TNFα production, in patients with severe disease141, while others have seen no differences142.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,745
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Flagged first, then by citations
Cited by
Sorted by citations
T cell responses in patients with COVID-19
Chen, Z., & John Wherry, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0402-6 · Cited by 797
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
Osuchowski, M. F., Winkler, M. S., Skirecki, T., Cajander, S., Shankar‐Hari, M., Lachmann, G., Monneret, G., Venet, F., Bauer, M. W., Brunkhorst, F. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00218-6 · Cited by 528
Natural killer cell immunotypes related to COVID-19 disease severity
Maucourant, C., Filipovic, I., Ponzetta, A., Aleman, S., Cornillet, M., Hertwig, L., Strunz, B., Lentini, A., Reinius, B., Brownlie, D., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd6832 · Cited by 493
COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
Arastehfar, A. A., Carvalho, A., van de Veerdonk, F. L., Jenks, J. D., Koehler, P. A., Krause, R., Cornely, O. A., Perlin, D. S., Lass‐Flörl, C., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6020091 · Cited by 429
SARS-CoV-2, COVID-19 and the aging immune system
Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021) · Nature Aging · doi:10.1038/s43587-021-00114-7 · Cited by 359
T cell response to SARS-CoV-2 infection in humans: A systematic review
Shrotri, M., van Schalkwyk, M. C., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245532 · Cited by 352
An immune-based biomarker signature is associated with mortality in COVID-19 patients
Abers, M. S., Delmonte, O. M., Ricotta, E., Fintzi, J., Fink, D. L., de Jesus, A. A., Zarember, K. A., Alehashemi, S., Oikonomou, V., Desai, J. V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144455 · Cited by 345
Lymphopenia during the COVID-19 infection: What it shows and what can be learned
Tavakolpour, S., Rakhshandehroo, T., Wei, E. X., & Rashidian, M. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.06.013 · Cited by 336
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., Santis, M. D., Acosta‐Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 319
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
Webb, B. J., Peltan, I. D., Jensen, P., Hoda, D., Hunter, B. D., Silver, A. E., Starr, N. J., Buckel, W. R., Grisel, N., Hummel, E., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30343-x · Cited by 300
Tebas, P., Yang, S., Boyer, J., Reuschel, E. L., Patel, A. R., Christensen-Quick, A., Andrade, V. M., Morrow, M. P., Kraynyak, K. A., Agnes, J. T., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100689 · Cited by 268
Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells
Witkowski, M., Tizian, C., Ferreira‐Gomes, M., Niemeyer, D., Jones, T. C., Heinrich, F., Frischbutter, S., Angermair, S., Hohnstein, T., Mattiola, I., et al. (2021) · Nature · doi:10.1038/s41586-021-04142-6 · Cited by 254
Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L., & Annunziato, F. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-00359-2 · Cited by 253
Self-citationThe SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes
Zhang, Y., Sun, H., Pei, R., Mao, B., Zhao, Z., Li, H., Lin, Y., & Lu, K. (2021) · Cell Discovery · doi:10.1038/s41421-021-00268-z · Cited by 255
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome
Chen, L. Y. C., Hoiland, R. L., Stukas, S. K., Wellington, C. L., & Sekhon, M. S. (2020) · European Respiratory Journal · doi:10.1183/13993003.03006-2020 · Cited by 243
Belsky, J. A., Tullius, B. P., Lamb, M. G., Sayegh, R., Stanek, J. R., & Auletta, J. J. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.022 · Cited by 238
Role of gut microbiota in infectious and inflammatory diseases
Maciel-Fiuza, M. F., Müller, G. C., Campos, D. M. S., Costa, P. D. S. S., Peruzzo, J., Bonamigo, R. R., Veit, T. D., & Vianna, F. S. L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1098386 · Cited by 263
Innate immune sensing of coronavirus and viral evasion strategies
Kasuga, Y., Zhu, B., Jang, K., & Yoo, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00602-1 · Cited by 236
Rha, M., Jeong, H. W., Ko, J. H., Choi, S. J., Seo, I., Lee, J. S., Sa, M., Kim, A. R., Joo, E., Ahn, J. Y., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.002 · Cited by 227
Vella, L. A., Giles, J. R., Baxter, A. E., Oldridge, D. A., Diorio, C. J., Kuri-Cervantes, L., Alanio, C., Pampena, M. B., Wu, J. E., Chen, Z., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf7570 · Cited by 225
Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue
Theoharides, T. C., Cholevas, C., Polyzoidis, K. S., & Politis, A. M. (2021) · BioFactors · doi:10.1002/biof.1726 · Cited by 227
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection
Synowiec, A., Szczepański, A., Barreto-Durán, E., Lie, L. K., & Pyrć, K. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00133-20 · Cited by 228
Gritti, G., Raimondi, F., Bottazzi, B., Ripamonti, D., Riva, I., Landi, F., Alborghetti, L., Frigeni, M., Damiani, M., Micò, M. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01299-x · Cited by 213
SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition
Sattler, A., Angermair, S., Stockmann, H., Heim, K. M., Khadzhynov, D., Treskatsch, S., Halleck, F., Kreis, M. E., & Kotsch, K. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140965 · Cited by 196
Activation or exhaustion of CD8+ T cells in patients with COVID-19
Rha, M., & Shin, E. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00750-4 · Cited by 201
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Huseni, M. A., Wang, L., Klementowicz, J. E., Yuen, K. C. Y., Bréart, B., Orr, C., Liu, L.-F., Li, Y., Gupta, V., Li, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100878 · Cited by 199
Sun, B., Tang, N., Peluso, M. J., Iyer, N. S., Torres, L., Donatelli, J. L., Munter, S. E., Nixon, C. C., Rutishauser, R. L., Rodríguez-Barraquer, I., et al. (2021) · Cells · doi:10.3390/cells10020386 · Cited by 190
T Cells: Warriors of SARS-CoV-2 Infection
de Candia, P., Prattichizzo, F., Garavelli, S., & Matarese, G. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.11.002 · Cited by 189
COVID-19 and Obesity: Dangerous Liaisons
Caci, G., Albini, A., Malerba, M., Noonan, D. M., Pochetti, P., & Polosa, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082511 · Cited by 192
Dong, W., Mead, H., Tian, L., Park, J., García, J. I., Jaramillo, S. A., Barr, T., Kollath, D. S., Coyne, V. K., Stone, N. E., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00964-21 · Cited by 183
T cell apoptosis characterizes severe Covid-19 disease
André, S., Picard, M., Cezar, R., Roux‐Dalvai, F., Alleaume‐Butaux, A., Soundaramourty, C., Cruz, A. S., Mendes‐Frias, A., Gotti, C., Leclercq, M., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00936-x · Cited by 185
Natural Killer Cell Dysfunction and Its Role in COVID-19
van Eeden, C., Khan, L., Osman, M. S., & Tervaert, J. W. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176351 · Cited by 179
SARS-CoV-2: characteristics and current advances in research
Yang, Y., Xiao, Z., Ye, K., He, X., Sun, B., Qin, Z., Yu, J., Yao, J., Wu, Q., Bao, Z., et al. (2020) · Virology Journal · doi:10.1186/s12985-020-01369-z · Cited by 168
Chioh, F. W., Fong, S., Young, B. E., Wu, K. X., Siau, A., Krishnan, S., Chan, Y., Carissimo, G., Teo, L. L., Gao, F., et al. (2021) · eLife · doi:10.7554/elife.64909 · Cited by 170
SARS-CoV-2-specific T cells in infection and vaccination
Bertoletti, A., Le Bert, N., Qui, M., & Tan, A. T. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00743-3 · Cited by 159
Metabolic programs define dysfunctional immune responses in severe COVID-19 patients
Thompson, E. A., Cascino, K., Ordoñez, A. A., Zhou, W., Vaghasia, A. M., Hamacher‐Brady, A., Brady, N. R., Sun, I., Wang, R., Rosenberg, A. Z., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108863 · Cited by 154
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies
Market, M., Angka, L., Martel, A. B., Bastin, D. J., Olanubi, O., Tennakoon, G., Boucher, D. M., Ng, J., Ardolino, M., & Auer, R. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01512 · Cited by 158
Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?
Theoharides, T. C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02696-0 · Cited by 156
Rivas, M. N., Ebinger, J. E., Wu, M., Sun, N., Braun, J. G., Sobhani, K., Eyk, J. E. V., Cheng, S. C., & Arditi, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci145157 · Cited by 152
Adaptive Immune Responses and Immunity to SARS-CoV-2
Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Ivkošić, I. E., & Parčina, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848582 · Cited by 162
Metabolic programs tailor T cell immunity in viral infection, cancer, and aging
Møller, S. H., Hsueh, P., Yu, Y.-R., Zhang, L., & Ho, P. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.003 · Cited by 154
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection
Munnur, D., Teo, Q. W., Eggermont, D., Lee, H. H. Y., Théry, F., Ho, J., van Leur, S. W., Ng, W. W., Siu, L. Y.-L., Beling, A., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01035-8 · Cited by 139
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I. O., Akdiş, M., Alves‐Correia, M., Antó, J. M., Arcolacı, A., Azkur, A. K., Azkur, D., et al. (2020) · Allergy · doi:10.1111/all.14449 · Cited by 140
Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics
Ritter, A., Kreis, N., Louwen, F., & Yuan, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165793 · Cited by 145
Immune response in COVID-19: what is next?
Li, Q., Wang, Y., Sun, Q., Knopf, J., i, M. H., Lin, L., Jiang, J., Shao, C., Li, P., He, X., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01015-x · Cited by 150
Gangaev, A., Ketelaars, S. L. C., Isaeva, O. I., Patiwael, S., Dopler, A., Hoefakker, K., De Biasi, S., Gibellini, L., Mussini, C., Guaraldi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22811-y · Cited by 111
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation
Shah, G. L., DeWolf, S., Lee, Y. J., Tamari, R., Dahi, P. B., Lavery, J. A., Ruiz, J. D., Devlin, S. M., Cho, C., Peled, J. U., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141777 · Cited by 121
Sayah, W., Berkane, I., Guermache, I., Sabri, M., Lakhal, F. Z., Rahali, S. Y., Djidjeli, A., Mahammed, L. L., Merah, F., Belaid, B., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155428 · Cited by 124
Single-cell immunology of SARS-CoV-2 infection
Tian, Y., Carpp, L. N., Miller, H. E. R., Zager, M. A., Newell, E. W., & Gottardo, R. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01131-y · Cited by 114
Sacchi, A., Grassi, G., Bordoni, V., Lorenzini, P., Cimini, E., Casetti, R., Tartaglia, E., Marchioni, L., Petrosillo, N., Palmieri, F., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03125-1 · Cited by 115
Yadav, P. D., Ella, R., Kumar, S., Patil, D., Mohandas, S., Shete, A. M., Vadrevu, K. M., Bhati, G., Sapkal, G. N., Kaushal, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21639-w · Cited by 105
The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome
Ganesh, R., Grach, S. L., Ghosh, A. K., Bierle, D. M., Salonen, B. R., Collins, N. M., Joshi, A. Y., Boeder, N., Anstine, C. V., Mueller, M. R., et al. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.11.033 · Cited by 105
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab
Meoni, G., Ghini, V., Maggi, L., Vignoli, A., Mazzoni, A., Salvati, L., Capone, M., Vanni, A., Tenori, L., Fontanari, P., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009243 · Cited by 91
Self-citationHaemophagocytic syndrome and COVID-19
Retamozo, S., Brito‐Zerón, P., Sisó‐Almirall, A., Flores-Chávez, A., Cárdenas, M. J. S., & Ramos‐Casals, M. (2021) · Clinical Rheumatology · doi:10.1007/s10067-020-05569-4 · Cited by 88
Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets
Hazeldine, J., & Lord, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680134 · Cited by 86
Abnormality in the NK-cell population is prolonged in severe COVID-19 patients
Leem, G., Cheon, S., Lee, H., Choi, S. J., Jeong, S., Kim, E.-S., Jeong, H. W., Jeong, H., Park, S., Ys, K., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.07.022 · Cited by 81
Basophils and Mast Cells in COVID-19 Pathogenesis
Murdaca, G., Gioacchino, M. D., Greco, M., Borro, M., Paladin, F., Petrarca, C., & Gangemi, S. (2021) · Cells · doi:10.3390/cells10102754 · Cited by 83
Hematopoietic responses to SARS-CoV-2 infection
Elahi, S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04220-6 · Cited by 79
Vannucchi, A. M., Sordi, B., Morettini, A., Nozzoli, C., Poggesi, L., Pieralli, F., Bartoloni, A., Atanasio, A., Miselli, F., Paoli, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01018-y · Cited by 73
Self-citationPeruzzi, B., Bencini, S., Capone, M., Mazzoni, A., Maggi, L., Salvati, L., Vanni, A., Orazzini, C., Nozzoli, C., Morettini, A., et al. (2020) · Immunology · doi:10.1111/imm.13254 · Cited by 72
Self-citationBertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 69
A scoping review of the pathophysiology of COVID-19
Marik, P. E., Iglesias, J. I., Varón, J., & Kory, P. D. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211048026 · Cited by 74
Al‐Nesf, M. A., Abdesselem, H., Bensmail, I., Ibrahim, S. I., Saeed, W., Mohammed, S., Razok, A., Alhussain, H., Aly, R. M. A., Maslamani, M. A. R. S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28639-4 · Cited by 69
Roberts, J., Pritchard, A. L., Treweeke, A. T., Rossi, A. G., Brace, N., Cahill, P. A., MacRury, S. M., Wei, J., & Megson, I. L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.629933 · Cited by 68
The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression
Huang, W. C., Li, M., Luo, G., Wu, X., Su, B., Zhao, L., Zhang, S., Chen, X., Jia, M., Zhu, J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001327 · Cited by 65
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study
IMPACC Manuscript Writing Team, Rouphael, N., Maecker, H. T., Montgomery, R. R., Diray‐Arce, J., Kleinstein, S. H., Altman, M. C., Bosinger, S. E., Eckalbar, W. L., Guan, L., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf3733 · Cited by 58
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
Kaye, A. G., & Siegel, R. (2020) · PeerJ · doi:10.7717/peerj.10322 · Cited by 62
Immunosenescence and inflamm-ageing in COVID-19
Zinatizadeh, M. R., Zarandi, P. K., Ghiasi, M., Kooshki, H., Mohammadi, M., Amani, J., & Rezaei, N. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101818 · Cited by 69
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F., & Cosmi, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101508 · Cited by 69
Self-citationHammer, Q., Dunst, J., Christ, W., Picarazzi, F., Wendorff, M., Momayyezi, P., Huhn, O., Netskar, H., Maleki, K. T., García, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110503 · Cited by 63
Mazzoni, A., Maggi, L., Capone, M., Spinicci, M., Salvati, L., Colao, M. G., Vanni, A., Kiros, S. T., Mencarini, J., Zammarchi, L., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048915 · Cited by 61
Self-citationShahbaz, S., Xu, L., Sligl, W., Osman, M. S., Bozorgmehr, N., Mashhouri, S., Redmond, D., Rosero, E. P., Walker, J. W. T., & Elahi, S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100446 · Cited by 63
Hypertension and its management in COVID-19 patients: The assorted view
Batiha, G. E., Gari, A. M., Elshony, N., Shaheen, H. M., Abubakar, M. B., Adeyemi, S. B., & Al-Kuraishy, H. M. (2021) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2021.200121 · Cited by 62
Zhao, H., Wang, T.-C., Li, X.-F., Zhang, N.-N., Li, L., Zhou, C., Deng, Y.-Q., Cao, T.-S., Yang, G., Li, R.-T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00861-4 · Cited by 60
Autoimmunity and COVID-19 – The microbiotal connection
Katz-Agranov, N. S., & Zandman‐Goddard, G. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102865 · Cited by 64
Tomić, S., Đokić, J., Stevanović, D., Ilić, N., Gruden‐Movsesijan, A., Dinić, M., Radojević, D., Bekić, M., Mitrović, N., Tomašević, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614599 · Cited by 59
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
Hasan, A., Al‐Ozairi, E., Albaqsumi, Z., Ahmad, R., & Al‐Mulla, F. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s280706 · Cited by 56
Immune responses in mildly versus critically ill COVID-19 patients
Nasrollahi, H., Talepoor, A. G., Saleh, Z., Vakili, M. E., Heydarinezhad, P., Karami, N., Noroozi, M., Meri, S., & Kalantar, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1077236 · Cited by 63
Zenarruzabeitia, O., Astarloa-Pando, G., Terrén, I., Orrantia, A., Pérez-Garay, R., Seijas, I., Arana, J. N., Imaz-Ayo, N., Pérez-Fernández, S., Arana‐Arri, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655934 · Cited by 54
Ghasemzadeh, M., Ghasemzadeh, A., & Hosseini, E. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.09.004 · Cited by 55
Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators
Ricci, D., Etna, M. P., Rizzo, F., Sandini, S., Severa, M., & Coccia, E. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137017 · Cited by 61
Favà, A., Donadeu, L., Sabé, N., Pernin, V., González‐Costello, J., Lladó, L., Meneghini, M., Charmetant, X., García‐Romero, E., Cachero, A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16570 · Cited by 59
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 53
Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections
von Massow, G., Oh, S. K. W., Lam, A. T., & Gustafsson, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741218 · Cited by 55
Gutiérrez‐Bautista, J. F., Rodríguez-Nicolás, A., Rosales‐Castillo, A., Jiménez, P., Garrido, F., Anderson, P. O., Ruiz‐Cabello, F., & López‐Ruz, M. Á. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.596553 · Cited by 56
Current status and prospects of IL-6–targeting therapy
Narazaki, M., & Kishimoto, T. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2097905 · Cited by 55
Pathogenesis‐directed therapy of 2019 novel coronavirus disease
Stratton, C. W., Tang, Y., & Lu, H. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26610 · Cited by 59
Lymphopenia: A useful predictor of COVID-19 disease severity and mortality
Toori, K. U., Qureshi, M. A., & Chaudhry, A. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.7.4085 · Cited by 53
Major reduction of NKT cells in patients with severe COVID-19 pneumonia
Zingaropoli, M. A., Perri, V., Pasculli, P., Dezza, F. C., Nijhawan, P., Savelloni, G., Torre, G. L., D’Agostino, C., Mengoni, F., Lichtner, M., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108630 · Cited by 56
Kim, D., Kim, Y., Seo, J.-W., Lee, J.-Y., Park, U., Ha, N., Koh, J., Park, H., Lee, J., Ro, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109798 · Cited by 54
Theoharides, T. C., Twahir, A., & Kempuraj, D. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.10.032 · Cited by 58
Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING?
Berthelot, J., Lioté, F., Maugars, Y., & Sibilia, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607069 · Cited by 53
SARS-CoV-2-Associated T-Cell Responses in the Presence of Humoral Immunodeficiency
Gupta, S., Su, H., Narsai, T., & Agrawal, S. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514193 · Cited by 51
Bao, C., Tao, X., Cui, W., Hao, Y., Zheng, S., Yi, B., Pan, T., Young, K. H., & Qian, W. (2021) · Experimental Hematology & Oncology · doi:10.1186/s40164-021-00199-1 · Cited by 47
“NK cells, as a part of innate immune system, play an important role during acute viral infection [5].”
BackgroundCOVID-19 in Immunosuppressed Children
Nicastro, E., Verdoni, L., Bettini, L. R., Zuin, G., Balduzzi, A., Montini, G., Biondi, A., & D’Antiga, L. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.629240 · Cited by 50
Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates
Malengier‐Devlies, B., Filtjens, J., Ahmadzadeh, K., Boeckx, B., Vandenhaute, J., Visscher, A. D., Bernaerts, E., Mitera, T., Jacobs, C., Vanderbeke, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861251 · Cited by 47
Li, C., Qian, W., Wei, X., Narasimhan, H., Wu, Y., Arish, M., Cheon, I. S., Tang, J., Santos, G. D. A., Li, Y., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn0136 · Cited by 51
Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19
Shi, J., Zhou, J., Zhang, X., Hu, W., Zhao, J., Wang, S., Wang, F., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.700152 · Cited by 48
Gligorijević, N., Stanić-Vučinić, D., Radomirović, M., Stojadinović, M., Olgica, N., Khulal, U., & Veličković, T. Ć. (2021) · Molecules · doi:10.3390/molecules26102834 · Cited by 48
Metadata
- Authors
- Mazzoni, A., Salvati, L., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Mencarini, J., Caporale, R., Peruzzi, B., Antonelli, A., Trotta, M., Zammarchi, L., Ciani, L., Gori, L., Lazzeri, C., Matucci, A., Vultaggio, A., Rossi, O., Almerigogna, F., Parronchi, P., Fontanari, P., Lavorini, F., Peris, A., Rossolini, G. M., Bartoloni, A., Romagnani, S., Liotta, F., Annunziato, F., & Cosmi, L.
- Affiliations
- University of Florence (IT)
- Corresponding author
- Annunziato, Francesco
- ORCID
- Mazzoni, Alessio
- Salvati, Lorenzo
- Maggi, Laura
- Capone, Manuela
- Vanni, Anna
- Spinicci, Michele
- Mencarini, Jessica
- Peruzzi, Benedetta
- Antonelli, Alberto
- Trotta, Michele
- Zammarchi, Lorenzo
- Gori, Leonardo
- Lazzeri, Chiara
- Matucci, Andrea
- Vultaggio, Alessandra
- Parronchi, Paola
- Lavorini, Federico
- Peris, Adriano
- Bartoloni, Alessandro
- Liotta, Francesco
- Annunziato, Francesco
- Cosmi, Lorenzo
- Venue
- Journal of Clinical Investigation
- Published
- 2020-08-04
- Volume
- 130
- Issue
- 9
- Pages
- 4694-4703
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7456250
- OpenAlex
- W3032533580
- Cited by
- 502
- References
- 45
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 47 · 2023: 70 · 2022: 105 · 2021: 181 · 2020: 70
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Funders
- Università degli Studi di Firenze
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- COVID-19 pandemic, SARS-CoV-2, interleukin-6, natural killer cells, CD8+ T cells, CD4+ T cells, granzyme A, T cell senescence, tocilizumab, cytokine storm, acute respiratory distress syndrome, intensive care
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, B-Lymphocytes, Critical Care, Cytotoxicity, Immunologic, Female, Humans, Killer Cells, Natural, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Interleukin-6, Cytokines, Coronavirus Infections, CD8-Positive T-Lymphocytes, Models, Immunological, Granzymes, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
